{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:22:13Z","timestamp":1791264133461,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10072-024-07599-1","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T01:01:31Z","timestamp":1716598891000},"page":"4699-4710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["From lab bench to hope: a review of gene therapies in clinical trials for Parkinson\u2019s disease and challenges"],"prefix":"10.1007","volume":"45","author":[{"given":"Julia","family":"Grote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-9857","authenticated-orcid":false,"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"6","key":"7599_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3727\/096368911X600948","volume":"21","author":"M Airavaara","year":"2012","unstructured":"Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B, Wang Y (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant 21(6):1213\u20131223","journal-title":"Cell Transplant"},{"key":"7599_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","volume":"9","author":"GE Alexander","year":"1986","unstructured":"Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357\u2013381","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"7599_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548\u2013560","journal-title":"JAMA"},{"key":"7599_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.semcancer.2018.07.005","volume":"53","author":"AA Ayanlaja","year":"2018","unstructured":"Ayanlaja AA, Zhang B, Ji G, Gao Y, Wang J, Kanwore K, Gao D (2018) The reversible effects of glial cell line-derived neurotrophic factor (GDNF) in the human brain. Semin Cancer Biol 53:212\u2013222","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"7599_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"S B\u00e4ck","year":"2013","unstructured":"B\u00e4ck S, Per\u00e4nen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, Voutilainen MH, Raasmaja A, Saarma M, M\u00e4nnist\u00f6 PT, Tuominen RK (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav 3(2):75\u201388","journal-title":"Brain Behav"},{"issue":"4","key":"7599_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","volume":"14","author":"KS Bankiewicz","year":"2006","unstructured":"Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14(4):564\u2013570","journal-title":"Mol Ther"},{"issue":"3","key":"7599_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JPD-202004","volume":"10","author":"RA Barker","year":"2020","unstructured":"Barker RA, Bj\u00f6rklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE (2020) GDNF and Parkinson\u2019s disease: where next? A summary from a recent workshop. J Parkinsons Dis 10(3):875\u2013891","journal-title":"J Parkinsons Dis"},{"key":"7599_CR8","doi-asserted-by":"publisher","first-page":"682597","DOI":"10.3389\/fncel.2021.682597","volume":"15","author":"O Bondarenko","year":"2021","unstructured":"Bondarenko O, Saarma M (2021) Neurotrophic factors in Parkinson\u2019s disease: clinical trials, open challenges and nanoparticle-mediated delivery to the brain. Front Cell Neurosci 15:682597","journal-title":"Front Cell Neurosci"},{"issue":"20","key":"7599_CR9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20):1662\u20131669","journal-title":"Neurology"},{"issue":"5","key":"7599_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, Boot B, Martin AJ, Nutt J, Thompson ME, Larson PS (2019) Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol 85(5):704\u2013714","journal-title":"Ann Neurol"},{"issue":"1","key":"7599_CR11","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, Li C, Liang GS, Meier A, Roberts EW, Pfau ML, Rodman JR, Bankiewicz KS, Larson PS (2022) Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. Neurology 98(1):e40\u2013e50","journal-title":"Neurology"},{"issue":"2","key":"7599_CR12","doi-asserted-by":"publisher","first-page":"e0169965","DOI":"10.1371\/journal.pone.0169965","volume":"12","author":"A Ciesielska","year":"2017","unstructured":"Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS (2017) Depletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS ONE 12(2):e0169965","journal-title":"PLoS ONE"},{"issue":"3","key":"7599_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000334527","volume":"11","author":"Y Du","year":"2013","unstructured":"Du Y, Zhang X, Tao Q, Chen S, Le W (2013) Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson\u2019s disease. Neurodegener Dis 11(3):113\u2013128","journal-title":"Neurodegener Dis"},{"issue":"2","key":"7599_CR14","first-page":"e34657","volume":"15","author":"O Dumbhare","year":"2023","unstructured":"Dumbhare O, Gaurkar SS (2023) A review of genetic and gene therapy for Parkinson\u2019s disease. Cureus 15(2):e34657","journal-title":"Cureus"},{"issue":"21","key":"7599_CR15","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980\u20131983","journal-title":"Neurology"},{"key":"7599_CR16","doi-asserted-by":"crossref","unstructured":"Eesmaa A, Yu LY, G\u00f6\u00f6s H, Danilova T, N\u00f5ges K, Pakarinen E, Varjosalo M, Lindahl M, Lindholm P, Saarma M (2022) CDNF interacts with ER chaperones and requires UPR sensors to promote neuronal survival. Int J Mol Sci 23(16):9489","DOI":"10.3390\/ijms23169489"},{"issue":"7","key":"7599_CR17","doi-asserted-by":"publisher","first-page":"e2324860","DOI":"10.1001\/jamanetworkopen.2023.24860","volume":"6","author":"M El Hayek","year":"2023","unstructured":"El Hayek M, Lobo Jofili Lopes JLM, LeLaurin JH, Gregory ME, Abi Nehme AM, McCall-Junkin P, Au KLK, Okun MS, Salloum RG (2023) Type, timing, frequency, and durability of outcome of physical therapy for Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open 6(7):e2324860","journal-title":"JAMA Netw Open"},{"issue":"3","key":"7599_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","volume":"27","author":"ME Emborg","year":"2007","unstructured":"Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D (2007) Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27(3):501\u2013509","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"7599_CR19","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1134\/S0006297921070063","volume":"86","author":"DV Eremin","year":"2021","unstructured":"Eremin DV, Ilchibaeva TV, Tsybko AS (2021) Cerebral Dopamine Neurotrophic Factor (CDNF): structure, functions, and therapeutic potential. Biochemistry (Mosc) 86(7):852\u2013866","journal-title":"Biochemistry (Mosc)"},{"issue":"17","key":"7599_CR20","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1089\/hum.1998.9.17-2527","volume":"9","author":"DS Fan","year":"1998","unstructured":"Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, Ichinose H, Nagatsu T, Kurtzman GJ, Ozawa K (1998) Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 9(17):2527\u20132535","journal-title":"Hum Gene Ther"},{"issue":"1","key":"7599_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59\u201365","journal-title":"Nat Biotechnol"},{"issue":"8","key":"7599_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Committee MDSE-BM (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33(8):1248\u20131266","journal-title":"Mov Disord"},{"key":"7599_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuropharm.2018.05.014","volume":"147","author":"R Grondin","year":"2019","unstructured":"Grondin R, Littrell OM, Zhang Z, Ai Y, Huettl P, Pomerleau F, Quintero JE, Andersen AH, Stenslik MJ, Bradley LH, Lemmon J, O\u2019Neill MJ, Gash DM, Gerhardt GA (2019) GDNF revisited: a novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution. Neuropharmacology 147:28\u201336","journal-title":"Neuropharmacology"},{"issue":"7","key":"7599_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","volume":"34","author":"JD Heiss","year":"2019","unstructured":"Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, Sinharay S, Scott G, Wu T, Federoff HJ, Zaghloul KA, Hallett M, Lonser RR, Bankiewicz KS (2019) Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov Disord 34(7):1073\u20131078","journal-title":"Mov Disord"},{"issue":"5","key":"7599_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH (2019) Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101(5):839\u2013862","journal-title":"Neuron"},{"issue":"4","key":"7599_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0963689719840290","volume":"28","author":"HJ Huttunen","year":"2019","unstructured":"Huttunen HJ, Saarma M (2019) CDNF protein therapy in Parkinson\u2019s disease. Cell Transplant 28(4):349\u2013366","journal-title":"Cell Transplant"},{"issue":"7","key":"7599_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/mds.29426","volume":"38","author":"HJ Huttunen","year":"2023","unstructured":"Huttunen HJ, Booms S, Sj\u00f6gren M, Kerstens V, Johansson J, Holmn\u00e4s R, Koskinen J, Kulesskaya N, Fazio P, Woolley M, Brady A, Williams J, Johnson D, Dailami N, Gray W, Levo R, Saarma M, Halldin C, Marjamaa J, Resendiz-Nieves J, Grubor I, Lind G, Eerola-Rautio J, Mertsalmi T, Andr\u00e9asson M, Paul G, Rinne J, Kivisaari R, Bjartmarz H, Almqvist P, Varrone A, Scheperjans F, Widner H, Svenningsson P (2023) Intraputamenal cerebral dopamine neurotrophic factor in Parkinson\u2019s disease: a randomized, double-blind, multicenter phase 1 trial. Mov Disord 38(7):1209\u20131222","journal-title":"Mov Disord"},{"issue":"9","key":"7599_CR28","doi-asserted-by":"publisher","first-page":"e14712","DOI":"10.15252\/emmm.202114712","volume":"13","author":"PW Hwu","year":"2021","unstructured":"Hwu PW, Kiening K, Anselm I, Compton DR, Nakajima T, Opladen T, Pearl PL, Roubertie A, Roujeau T, Muramatsu SI (2021) Gene therapy in the putamen for curing AADC deficiency and Parkinson\u2019s disease. EMBO Mol Med 13(9):e14712","journal-title":"EMBO Mol Med"},{"issue":"9579","key":"7599_CR29","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369(9579):2097\u20132105","journal-title":"Lancet"},{"issue":"2","key":"7599_CR30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10787-023-01141-z","volume":"31","author":"S Kartik","year":"2023","unstructured":"Kartik S, Pal R, Chaudhary MJ, Nath R, Kumar M, Binwal M, Bawankule DU (2023) Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson\u2019s disease. Inflammopharmacology 31(2):927\u2013941","journal-title":"Inflammopharmacology"},{"issue":"28","key":"7599_CR31","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","volume":"30","author":"AP Kells","year":"2010","unstructured":"Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30(28):9567\u20139577","journal-title":"J Neurosci"},{"issue":"2","key":"7599_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nbd.2011.10.004","volume":"48","author":"AP Kells","year":"2012","unstructured":"Kells AP, Forsayeth J, Bankiewicz KS (2012) Glial-derived neurotrophic factor gene transfer for Parkinson\u2019s disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 48(2):228\u2013235","journal-title":"Neurobiol Dis"},{"issue":"1\u20132","key":"7599_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0006-8993(97)01100-1","volume":"777","author":"PA Lapchak","year":"1997","unstructured":"Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S (1997) Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson\u2019s disease. Brain Res 777(1\u20132):153\u2013160","journal-title":"Brain Res"},{"issue":"4","key":"7599_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (2011) AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309\u2013319","journal-title":"Lancet Neurol"},{"issue":"Pt B","key":"7599_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nbd.2016.07.009","volume":"97","author":"M Lindahl","year":"2017","unstructured":"Lindahl M, Saarma M, Lindholm P (2017) Unconventional neurotrophic factors CDNF and MANF: structure, physiological functions and therapeutic potential. Neurobiol Dis 97(Pt B):90\u2013102","journal-title":"Neurobiol Dis"},{"issue":"10","key":"7599_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ (2023) AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov 22(10):789\u2013806","journal-title":"Nat Rev Drug Discov"},{"key":"7599_CR37","doi-asserted-by":"publisher","first-page":"108594","DOI":"10.1016\/j.pharmthera.2024.108594","volume":"254","author":"H L\u00f5helaid","year":"2024","unstructured":"L\u00f5helaid H, Saarma M, Airavaara M (2024) CDNF and ER stress: Pharmacology and therapeutic possibilities. Pharmacol Ther 254:108594","journal-title":"Pharmacol Ther"},{"issue":"5592","key":"7599_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1074549","volume":"298","author":"J Luo","year":"2002","unstructured":"Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ (2002) Subthalamic GAD gene therapy in a Parkinson\u2019s disease rat model. Science 298(5592):425\u2013429","journal-title":"Science"},{"issue":"Suppl 2","key":"7599_CR39","first-page":"S32","volume":"17","author":"CD Marsden","year":"1994","unstructured":"Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson\u2019s disease. Clin Neuropharmacol 17(Suppl 2):S32-44","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"7599_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS (2012) Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther 23(4):377\u2013381","journal-title":"Hum Gene Ther"},{"issue":"3","key":"7599_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/10430340252792486","volume":"13","author":"S Muramatsu","year":"2002","unstructured":"Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K (2002) Behavioral recovery in a primate model of Parkinson\u2019s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13(3):345\u2013354","journal-title":"Hum Gene Ther"},{"issue":"9","key":"7599_CR42","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2010","unstructured":"Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther 18(9):1731\u20131735","journal-title":"Mol Ther"},{"key":"7599_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12974-014-0209-0","volume":"11","author":"R Nadella","year":"2014","unstructured":"Nadella R, Voutilainen MH, Saarma M, Gonzalez-Barrios JA, Leon-Chavez BA, Jim\u00e9nez JM, Jim\u00e9nez SH, Escobedo L, Martinez-Fong D (2014) Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. J Neuroinflammation 11:209","journal-title":"J Neuroinflammation"},{"issue":"7","key":"7599_CR44","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A (2017) Long-term follow-up of a randomized AAV2-. JCI Insight 2(7):e90133","journal-title":"JCI Insight"},{"key":"7599_CR45","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","volume":"20","author":"M Nonnenmacher","year":"2021","unstructured":"Nonnenmacher M, Wang W, Child MA, Ren XQ, Huang C, Ren AZ, Tocci J, Chen Q, Bittner K, Tyson K, Pande N, Chung CH, Paul SM, Hou J (2021) Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol Ther Methods Clin Dev 20:366\u2013378","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"7599_CR46","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1523\/JNEUROSCI.22-12-04942.2002","volume":"22","author":"S Palfi","year":"2002","unstructured":"Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, D\u00e9glon N, Hantraye P, Aebischer P, Kordower JH (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22(12):4942\u20134954","journal-title":"J Neurosci"},{"issue":"9","key":"7599_CR47","doi-asserted-by":"publisher","first-page":"e0184262","DOI":"10.1371\/journal.pone.0184262","volume":"12","author":"H-J Park","year":"2017","unstructured":"Park H-J, Ryu D, Parmar M, Giasson BI, McFarland NR (2017) The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. PLoS ONE 12(9):e0184262","journal-title":"PLoS ONE"},{"issue":"2","key":"7599_CR48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00204-017-2073-z","volume":"92","author":"S Potdar","year":"2018","unstructured":"Potdar S, Parmar MS, Ray SD, Cavanaugh JE (2018) Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. Arch Toxicol 92(2):669\u2013677","journal-title":"Arch Toxicol"},{"key":"7599_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","volume":"248","author":"X Ren","year":"2013","unstructured":"Ren X, Zhang T, Gong X, Hu G, Ding W, Wang X (2013) AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol 248:148\u2013156","journal-title":"Exp Neurol"},{"key":"7599_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.brainres.2014.05.028","volume":"1573","author":"KM Rose","year":"2014","unstructured":"Rose KM, Parmar MS, Cavanaugh JE (2014) Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure. Brain Res 1573:37\u201343","journal-title":"Brain Res"},{"issue":"3","key":"7599_CR51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/gt.2012.27","volume":"20","author":"EA Salegio","year":"2013","unstructured":"Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S, Beyer J, Forsayeth J, Bankiewicz KS (2013) Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther 20(3):348\u2013352","journal-title":"Gene Ther"},{"issue":"11","key":"7599_CR52","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1089\/10430340050083243","volume":"11","author":"Y Shen","year":"2000","unstructured":"Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, Mizukami H, Urabe M, Kume A, Nagatsu I, Urano F, Suzuki T, Ichinose H, Nagatsu T, Monahan J, Nakano I, Ozawa K (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson\u2019s disease. Hum Gene Ther 11(11):1509\u20131519","journal-title":"Hum Gene Ther"},{"key":"7599_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbd.2014.01.009","volume":"65","author":"J Tereshchenko","year":"2014","unstructured":"Tereshchenko J, Maddalena A, B\u00e4hr M, K\u00fcgler S (2014) Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson\u2019s disease. Neurobiol Dis 65:35\u201342","journal-title":"Neurobiol Dis"},{"issue":"6","key":"7599_CR54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bpa.12730","volume":"29","author":"S Virachit","year":"2019","unstructured":"Virachit S, Mathews KJ, Cottam V, Werry E, Galli E, Rappou E, Lindholm P, Saarma M, Halliday GM, Shannon Weickert C, Double KL (2019) Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson\u2019s disease. Brain Pathol 29(6):813\u2013825","journal-title":"Brain Pathol"},{"issue":"10\u201311","key":"7599_CR55","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41434-023-00419-9","volume":"30","author":"CH Wong","year":"2023","unstructured":"Wong CH, Li D, Wang N, Gruber J, Lo AW, Conti RM (2023) The estimated annual financial impact of gene therapy in the United States. Gene Ther 30(10\u201311):761\u2013773","journal-title":"Gene Ther"},{"key":"7599_CR56","doi-asserted-by":"crossref","unstructured":"Zhang GL, Wang LH, Liu XY, Zhang YX, Hu MY, Liu L, Fang YY, Mu Y, Zhao Y, Huang SH, Liu T, Wang XJ (2018) Cerebral Dopamine Neurotrophic Factor (CDNF) has neuroprotective effects against cerebral ischemia that may occur through the endoplasmic reticulum stress pathway. Int J Mol Sci 19(7):1905","DOI":"10.3390\/ijms19071905"},{"issue":"1","key":"7599_CR57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molbrainres.2004.06.029","volume":"134","author":"JS Zheng","year":"2005","unstructured":"Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF (2005) Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson\u2019s disease. Brain Res Mol Brain Res 134(1):155\u2013161","journal-title":"Brain Res Mol Brain Res"},{"key":"7599_CR58","doi-asserted-by":"publisher","first-page":"988914","DOI":"10.3389\/fnmol.2022.988914","volume":"15","author":"K Zhou","year":"2022","unstructured":"Zhou K, Han J, Wang Y, Zhang Y, Zhu C (2022) Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases. Front Mol Neurosci 15:988914","journal-title":"Front Mol Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07599-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07599-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07599-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T10:14:11Z","timestamp":1727172851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07599-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7599"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07599-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required for this article as no datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This does not apply to this article, as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Written consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"This literature review did not involve any original research with human participants or\u00a0animals, thus informed consent was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}